Seed Investment

metaLinear is a biotechnology company focused on the identification and validation of new drug targets for difficult to treat bacterial infections.

metaLinear's founder has extensive scientific and business expertise in the commercialisation of protein engineering that underpins metaLinear's business. The development of new therapies to treat multi-drug resistant infections is a priority for governments, healthcare providers and industry. metaLinear's technology has the potential to identify important new drug targets and accelerate the development of new classes of antibiotics for the treatment of serious infections. 

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Nick Wright

view complete team

Contact us

Tel: 01625 344300